Rupaly Pandé
A5042274599- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Esophageal and GI Pathology
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Screening and Detection
- Nutrition and Health in Aging
- Radiomics and Machine Learning in Medical Imaging
- Neuroblastoma Research and Treatments
- Palliative Care and End-of-Life Issues
- Spinal Fractures and Fixation Techniques
- Spine and Intervertebral Disc Pathology
- Childhood Cancer Survivors' Quality of Life
- Intraperitoneal and Appendiceal Malignancies
- Esophageal Cancer Research and Treatment
- Virology and Viral Diseases
- Multiple and Secondary Primary Cancers
- Medical Imaging and Analysis
- Animal Virus Infections Studies
NIHR Surgical Reconstruction and Microbiology Research Centre
2020-2025
Queen Elizabeth Hospital Birmingham
2019-2024
Queen Elizabeth Hospital
2018-2024
University Hospitals Birmingham NHS Foundation Trust
2019-2024
National Health Service
2024
University of Birmingham
2022-2024
Vall d'Hebron Hospital Universitari
2023
St James's University Hospital
2016
<h3>Importance</h3> The benefit of adjuvant chemotherapy after resection pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. <h3>Objective</h3> To assess the association overall survival (OS) in patients FOLFIRINOX treatment. <h3>Design, Setting, Participants</h3> This international, multicenter, retrospective cohort study was conducted from January 1, 2012, to December 31, 2018. An existing...
Importance Preoperative chemo(radio)therapy is increasingly used in patients with localized pancreatic adenocarcinoma, leading to pathological complete response (pCR) a small subset of patients. However, multicenter studies in-depth data about pCR are lacking. Objective To investigate the incidence, outcome, and risk factors after preoperative chemo(radio)therapy. Design, Setting, Participants This observational, international, cohort study assessed all consecutive pathology-proven...
Abstract Background Disease recurrence remains one of the biggest concerns in patients after resection pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most experience local and/or distant PDAC within 2 years. High-level evidence regarding benefits recurrence-focused surveillance is missing, and impact early detection treatment on survival quality life unknown. In European countries, follow-up surgery for currently lacking. Consequently, guidelines...
Objective: The aim of the present study was to compare long-term post-resection oncological outcomes between A-IPMN and PDAC. Summary Background Data: Knowledge long term (e.g recurrence survival data) comparing adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN) pancreatic ductal (PDAC) is scarce. Methods: Patients undergoing resection (2010-2020) for were identified retrospectively 18 academic centres compared with PDAC patients same time-period. Propensity-score...
Abstract Background The clinical impact of adjuvant chemotherapy after resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia is unclear. aim this study was to identify factors related receipt and its on recurrence survival. Methods This a multicentre retrospective patients undergoing pancreatic between January 2010 December 2020 at 18 centres. Recurrence survival outcomes who did not receive were compared using propensity score matching. Results Of 459 underwent...
To validate the prognostic value of PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant FOLFIRINOX. The PANAMA-score was developed guide prognostication therapy PDAC. As this score focuses on risk residual disease resection, it might also be able select who therapy. This retrospective international multicenter...
Objective: This international multicentre cohort study aims to identify recurrence patterns and treatment of first second in a large patients after pancreatic resection for adenocarcinoma arising from IPMN. Summary Background Data: Recurrence post IPMN are poorly explored. Method: Patients undergoing between January 2010 December 2020 at 18 centres were identified. Survival analysis was performed by the Kaplan-Meier log rank test multivariable logistic regression Cox-Proportional Hazards...
Abstract Background Pancreatoduodenectomy (PD) is associated with significant postoperative morbidity. Surgeons should have a sound understanding of the potential complications for consenting and benchmarking purposes. Furthermore, preoperative identification high-risk patients can guide patient selection potentially allow targeted prehabilitation and/or individualized treatment regimens. Using large multicentre cohort, this study aimed to calculate incidence all PD identify risk factors....
Abstract Background The clinico-oncological outcomes of precursor epithelial subtypes adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN) are limited to small cohort studies. Differences in recurrence patterns and response adjuvant chemotherapy between A-IPMN unknown. Methods Clincopathological features, long-term patients undergoing pancreatic resection (2010–2020) for were reported 18 academic centres worldwide. Precursor subtype groups compared using uni-...
Para-aortic lymph nodes (PALN) are found in the aortocaval groove and they staged as metastatic disease if involved by pancreatic ductal adenocarcinoma (PDAC). The data literature is conflicting with some studies having associated PALN involvement poor prognosis, while others not sharing same results. resection included standard lymphadenectomy during resections per International Study Group for Pancreatic Surgery there no consensus on management of these cases.
Preoperative FOLFIRINOX chemotherapy is increasingly administered to patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) improve overall survival (OS). Multicenter studies reporting on the impact from number of preoperative cycles use adjuvant in relation outcomes this setting are lacking. This study aimed assess outcome pancreatectomy after FOLFIRINOX, including predictors OS.This international multicenter retrospective cohort included 31 centers 19...
Level 1 evidence from randomized trials demonstrates less complication when jaundiced patients with resectable pancreatic cancer proceed directly to surgery, rather than undergo preoperative biliary drainage (PBD) first. Although "fast track" surgery significantly increases the resectability rate, it is unknown whether this translates into a survival benefit. This study evaluated effect of upfront on long-term using an intention-to-treat (ITT) analysis.Patients were identified prospectively...
Early treatment is the only potential cure for periampullary cancer. The pathway to surgery complex and involves multiple procedures across local specialist hospitals. aim of this study was analyse variability within pathway, its impact on cost outcomes. Patients undergoing cancer (2011–2016) were identified retrospectively their analysed. who had early (shortest quartile, Q1) compared with those having late (longest Q4). A total 483 patients included in study, 121 124 Q1 Q4 respectively....